Remote ischemic preconditioning for Heart Failure
Study Summary
This trial is studying whether a treatment called remote ischemic preconditioning can reduce contrast-associated acute kidney injury, functional capacity, and major adverse kidney events in patients with congestive heart failure undergoing cardiac catheterization and/or percutaneous coronary intervention.
- Heart Failure
- Percutaneous Coronary Intervention (PCI)
- Acute Kidney Injury
- Prophylaxis of Contrast-induced Nephropathy
- Coronary Angiography
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: 3 months
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Remote ischemic preconditioning
1 of 2
Sham remote ischemic preconditioning
1 of 2
Active Control
Non-Treatment Group
240 Total Participants · 2 Treatment Groups
Primary Treatment: Remote ischemic preconditioning · Has Placebo Group · Phase 2 & 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many individuals are taking part in this clinical research?
"The most recent information on clinicaltrials.gov says that this trial is still recruiting patients. The posting date was 11/1/2021, and the last update occurred on 11/2/2022. There are plans to enroll 240 participants at 2 locations." - Anonymous Online Contributor
Are we currently looking for new participants in this clinical trial?
"This research project is still recruiting test subjects, with the first posting on clinicaltrials.gov being November 1st, 2021 and the most recent update coming on November 2nd, 2022." - Anonymous Online Contributor